Stem Cells
Therapies
Stem Cells Therapies
The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).
FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.
Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.
Check the full list of patients who received stem cell therapy derived from FamiCord labs.
List last update: 06.2026
List of patients who received stem cells from FamiCord Group laboratories
| Lp. | Source | Source type | Diagnosis | Medical field | Year of application | Therapy | Country | Age of recipient |
|---|---|---|---|---|---|---|---|---|
| 1401 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Germany | 21 |
| 1402 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Denmark | 65 |
| 1403 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Romania | 25 |
| 1404 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Italy | 27 |
| 1405 | Apheresis | Allogeneic | Polycythaemia Vera | Hematology | 2025 | Standard Therapy | Germany | 61 |
| 1406 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 25 |
| 1407 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 51 |
| 1408 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Germany | 70 |
| 1409 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 53 |
| 1410 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Lithuania | 61 |
| 1411 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Russian Federation | 49 |
| 1412 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 36 |
| 1413 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 62 |
| 1414 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 54 |
| 1415 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 74 |
| 1416 | Apheresis | Allogeneic | NHL Non-Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | Poland | 49 |
| 1417 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 62 |
| 1418 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2025 | Standard Therapy | USA | 74 |
| 1419 | Apheresis | Allogeneic | NHL Non-Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | Argentine | 57 |
| 1420 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Germany | 56 |
| 1421 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Belgium | 71 |
| 1422 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Spain | 59 |
| 1423 | Apheresis | Allogeneic | Other Myelofibrosis/Myelosclerosis | Hematology | 2025 | Standard Therapy | USA | 65 |
| 1424 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 14 |
| 1425 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Denmark | 57 |
| 1426 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 68 |
| 1427 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 51 |
| 1428 | Apheresis | Allogeneic | Richter Transformation CDLBCC | Hematology | 2025 | Standard Therapy | Germany | 68 |
| 1429 | Apheresis | Allogeneic | Acute Myelogenous Leukemia-MR | Hematology | 2025 | Standard Therapy | Russian Federation | 16 |
| 1430 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 63 |
| 1431 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 66 |
| 1432 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 50 |
| 1433 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 38 |
| 1434 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 43 |
| 1435 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 74 |
| 1436 | Apheresis | Allogeneic | T-cell Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 51 |
| 1437 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 59 |
| 1438 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 66 |
| 1439 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 68 |
| 1440 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 33 |
| 1441 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 48 |
| 1442 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Netherlands | 66 |
| 1443 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 57 |
| 1444 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Belgium | 56 |
| 1445 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 55 |
| 1446 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 24 |
| 1447 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Italy | 61 |
| 1448 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 71 |
| 1449 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Canada | 53 |
| 1450 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2025 | Standard Therapy | Germany | 62 |
| 1451 | Apheresis | Autologous | Mantle Cell Lymphoma | Hematology | 2025 | Standard Therapy | Germany | 45 |
| 1452 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2025 | Standard Therapy | Germany | 61 |
| 1453 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2025 | Standard Therapy | Germany | 32 |
| 1454 | Apheresis | Autologous | Diffuse Large B-Cell Lymphoma | Hematology | 2025 | Standard Therapy | Germany | 62 |
| 1455 | Apheresis | Autologous | Central Nervous System Lymphoma | Hematology | 2025 | Standard Therapy | Germany | 75 |
| 1456 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2025 | Standard Therapy | Germany | 70 |
| 1457 | Cord Tissue | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Romania | 6 |
| 1458 | Cord Tissue | Allogeneic – Related | Autism | Neurology | 2024 | Experimental Therapy | Romania | 6 |
| 1459 | Cord Tissue | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Romania | 4 |
| 1460 | Cord Tissue | Allogeneic – Related | Autism | Neurology | 2024 | Experimental Therapy | Romania | 6 |
| 1461 | Cord Tissue | Allogeneic – Unrelated | Degenerative and Traumatic Cartilage | Orthopedics | 2024 | Experimental Therapy | Poland | 50 |
| 1462 | Cord Tissue | Allogeneic – Unrelated | Degenerative and Traumatic Cartilage | Orthopedics | 2024 | Experimental Therapy | Poland | 49 |
| 1463 | Cord Tissue | Allogeneic – Unrelated | Degenerative and Traumatic Cartilage | Orthopedics | 2024 | Experimental Therapy | Poland | 58 |
| 1464 | Cord Tissue | Allogeneic – Unrelated | Graft Versus Host Disease | Hematology | 2024 | Experimental Therapy | Poland | 7 |
| 1465 | Cord Tissue | Allogeneic – Unrelated | Graft Versus Host Disease | Hematology | 2024 | Experimental Therapy | Poland | 15 |
| 1466 | Cord Tissue | Allogeneic – Unrelated | Ovarian Dysfunction | Gynecology | 2024 | Experimental Therapy | Poland | 48 |
| 1467 | Cord Tissue | Allogeneic – Related | Severe Pulmonary Hypertension +Mitral Regurgitation | Cardiovascular/Pulmonary | 2024 | Experimental Therapy | Romania | 2 |
| 1468 | Cord Tissue | Allogeneic – Unrelated | Amyotrophic lateral sclerosis | Neurology | 2024 | Experimental Therapy | Poland | 57 |
| 1469 | Cord Tissue | Allogeneic – Unrelated | Degenerative and traumatic cartilage damage | Orthopedics | 2024 | Experimental Therapy | Poland | 68 |
| 1470 | Cord Tissue | Allogeneic – Related | Autism | Neurology | 2024 | Experimental Therapy | Romania | 17 |
| 1471 | Cord Tissue | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Romania | 7 |
| 1472 | Cord Tissue | Allogeneic – Unrelated | Degenerative and traumatic cartilage damage | Orthopedics | 2024 | Experimental Therapy | Poland | 61 |
| 1473 | Cord Tissue | Allogeneic – Unrelated | Degenerative and traumatic cartilage damage | Orthopedics | 2024 | Experimental Therapy | Poland | 45 |
| 1474 | Cord Tissue | Allogeneic – Unrelated | Amyotrophic lateral sclerosis | Neurology | 2024 | Experimental Therapy | Poland | 56 |
| 1475 | Cord Tissue | Allogeneic – Unrelated | Graft-versus-host disease | Hematology | 2024 | Experimental Therapy | Poland | 0 |
| 1476 | Cord Tissue | Allogeneic – Unrelated | Amyotrophic lateral sclerosis | Neurology | 2024 | Experimental Therapy | Poland | 39 |
| 1477 | Cord Tissue | Allogeneic – Unrelated | GvHD | Neurology | 2024 | Experimental Therapy | Poland | 9 |
| 1478 | Cord Tissue | Allogeneic – Unrelated | Cerebral palsy | Neurology | 2024 | Experimental Therapy | Poland | 5 |
| 1479 | Cord Tissue | Allogeneic – Unrelated | Cerebral palsy | Neurology | 2024 | Experimental Therapy | Poland | 13 |
| 1480 | Cord Tissue | Allogeneic – Unrelated | Leukodystrophy | Neurology | 2024 | Experimental Therapy | Poland | 1 |
| 1481 | Cord Tissue | Allogeneic – Unrelated | Cerebral Palsy | Neurology | 2024 | Experimental Therapy | Poland | 7 |
| 1482 | Cord Tissue | Allogeneic – Unrelated | Leukodystrophy | Neurology | 2024 | Experimental Therapy | Poland | 1 |
| 1483 | Cord Tissue | Allogeneic – Unrelated | Cerebellar-spinal ataxia | Neurology | 2024 | Experimental Therapy | Poland | 35 |
| 1484 | Cord Tissue | Allogeneic – Unrelated | Leukodystrophy | Neurology | 2024 | Experimental Therapy | Poland | 1 |
| 1485 | Cord Tissue | Allogeneic – Unrelated | Cerebral Palsy | Neurology | 2024 | Experimental Therapy | Poland | 4 |
| 1486 | Cord Blood | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Romania | 11 |
| 1487 | Cord Blood | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Romania | 10 |
| 1488 | Cord Blood | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Romania | 6 |
| 1489 | Cord Blood | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Romania | 4 |
| 1490 | Cord Blood | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Romania | 5 |
| 1491 | Cord Blood | Allogeneic | Cerebral Palsy | Neurology | 2024 | Experimental Therapy | Poland | 3 |
| 1492 | Cord Blood | Allogeneic | Cerebral Palsy | Neurology | 2024 | Experimental Therapy | Poland | 7 |
| 1493 | Cord Blood | Autologous | CP | Neurology | 2024 | Experimental Therapy | Hungary | 4 |
| 1494 | Cord Blood | Autologous | Pervasive Developmental Disorder | Neurology | 2024 | Experimental Therapy | Poland | 3 |
| 1495 | Cord Blood | Autologous | Pervasive Developmental Disorder | Neurology | 2024 | Experimental Therapy | Poland | 5 |
| 1496 | Cord Blood | Autologous | Pervasive developmental disorder | Neurology | 2024 | Experimental Therapy | Poland | 4 |
| 1497 | Cord Blood | Allogeneic – Related | fanconi aplastic anemia | Hematology | 2024 | Standard Therapy | Turkey | 12 |
| 1498 | Cord Blood | Autologous | Neuroblastoma | Neurology | 2024 | Standard Therapy | Poland | 4 |
| 1499 | Cord Blood | Autologous | Pervasive developmental disorder | Neurology | 2024 | Experimental Therapy | Poland | 9 |
| 1500 | Cord Blood | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Slovakia | 4 |